ArticleDrug design, development and therapy2026
Hematological Safety of Contezolid versus Linezolid in Stage 5 Chronic Kidney Disease: An Active-Comparator New-User Retrospective Cohort Study.
Article in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Current Status and Perspectives of Antibacterial Agents Belonging to 2-Oxazolidinones.Pharmaceuticals (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Contezolid is a novel oxazolidinone antibiotic approved for treating Gram-positive bacterial infections. Unlike linezolid, it lacks myelosuppressive toxicity, a potential advantage in patients with renal failure who are prone to anemia. However, data on hematologic safety of contezolid in this population remains limited. This study evaluates the hematological effects of contezolid in patients with renal failure. Methods: This two-center retrospective cohort study employed an active-comparator new-user design to compare the hematological safety of contezolid versus linezolid in patients with renal failure. The primary outcome was the impact of contezolid and linezolid on hemoglobin levels. The secondary outcomes included microbial eradication, clinical cure rate and adverse reaction. Propensity score matching and multivariate logistic regression were used to adjust for confounding factors. Results: A total of 290 patients were enrolled, with 122 in the contezolid group and 168 in the linezolid group. Severe anemia occurred in 14.75% of patients receiving contezolid versus 46.43% with linezolid ( Conclusion: Compared with linezolid, contezolid was associated with a lower risk of clinically significant hemoglobin decline among patients with renal failure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.